Lipid Disorders
Conference Coverage
Post-hoc analysis offers hope for novel cholesterol drug
A second look at vupanorsen revealed its effects on VLDL and remnant cholesterol levels in TRANSLATE-TIMI 70, which had disappointing primary...
Guidelines
ADA updates on finerenone, SGLT2 inhibitors, and race-based eGFR
ADA has made an interim change to its latest Standards of Medical Care, an update based on trial evidence and consensus about finerenone, SGLT2...
Conference Coverage
CTO PCI success rates rising, with blip during COVID-19, registry shows
Updated results from the PROGRESS-CTO registry of chronic total occlusion percutaneous coronary angioplasty cases reports improving outcomes over...
From the Journals
Antipsychotic tied to dose-related weight gain, higher cholesterol
Risperidone is an antipsychotic with a “medium to high metabolic risk profile.”
Conference Coverage
Obesity in adolescence raises risk for adult type 1 diabetes
Risk of type 1 diabetes was doubled compared with adolescents with optimal body mass index in a study of military recruits.
Conference Coverage
Tirzepatide powers ‘unprecedented’ weight loss in SURMOUNT-1
The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the...
Conference Coverage
Will tirzepatide slow kidney function decline in type 2 diabetes?
Compared to insulin glargine, tirzepatide was associated with significantly less new-onset macroalbuminuria in patients with T2D at high...
From the Journals
Omega-3 supplement sweet spot found for BP reduction
A meta-analysis of almost 5,000 people found that 2-3 g of omega-3 fatty acids a day is optimal for reducing blood pressure in people with high BP...
Conference Coverage
LDL lowering to specific targets may offset risk from high Lp(a)
Researchers have developed a novel app to show how the increased risk of coronary events due to elevated lipoprotein(a) levels can be countered by...
From the Journals
Very high HDL-C: Too much of a good thing?
“Very high HDL levels are associated with increased risk of adverse outcomes, not lower risk, as previously thought.”
From the Journals
SGLT2 inhibitors as first-line therapy in type 2 diabetes?
Real-world study finds heart failure hospitalization reduction, compared with metformin but not MI, stroke, or overall mortality and with greater...